| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Fusion Protein:RNF213-ALK |
Fusion Protein Summary |
 Fusion gene summary |
| Fusion partner gene information | Fusion gene name: RNF213-ALK | FusionPDB ID: 74961 | FusionGDB2.0 ID: 74961 | Hgene | Tgene | Gene symbol | RNF213 | ALK | Gene ID | 57674 | 238 |
| Gene name | ring finger protein 213 | ALK receptor tyrosine kinase | |
| Synonyms | ALO17|C17orf27|KIAA1618|MYMY2|MYSTR|NET57 | CD246|NBLST3 | |
| Cytomap | 17q25.3 | 2p23.2-p23.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | E3 ubiquitin-protein ligase RNF213ALK lymphoma oligomerization partner on chromosome 17RING-type E3 ubiquitin transferase RNF213mysterin | ALK tyrosine kinase receptorCD246 antigenanaplastic lymphoma receptor tyrosine kinasemutant anaplastic lymphoma kinase | |
| Modification date | 20200313 | 20200329 | |
| UniProtAcc | Q63HN8 | Q96BT7 | |
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000456466, ENST00000508628, ENST00000582970, ENST00000319921, ENST00000336301, ENST00000427003, | ENST00000431873, ENST00000498037, ENST00000389048, |
| Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 34 X 32 X 16=17408 | 56 X 74 X 20=82880 |
| # samples | 41 | 57 | |
| ** MAII score | log2(41/17408*10)=-5.40798274174489 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(57/82880*10)=-7.18391827352181 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context (manual curation of fusion genes in FusionPDB) | PubMed: RNF213 [Title/Abstract] AND ALK [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | |||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | RNF213 | GO:0016567 | protein ubiquitination | 21799892 |
| Hgene | RNF213 | GO:0051260 | protein homooligomerization | 24658080|26126547 |
| Hgene | RNF213 | GO:0051865 | protein autoubiquitination | 21799892 |
| Tgene | ALK | GO:0016310 | phosphorylation | 9174053 |
| Tgene | ALK | GO:0046777 | protein autophosphorylation | 9174053 |
| Fusion gene breakpoints across RNF213 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across ALK (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Fusion Gene Sample Information |
| Fusion gene information from FusionGDB2.0. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerKB3 | . | . | RNF213 | chr17 | 78302277 | ALK | chr2 | 29446394 | - |
Top |
Fusion ORF Analysis |
| Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000508628 | RNF213 | chr17 | 78302277 | ENST00000389048 | ALK | chr2 | 29446394 | - | 5950 | 3809 | 145 | 5499 | 1784 | |
| ENST00000456466 | RNF213 | chr17 | 78302277 | ENST00000389048 | ALK | chr2 | 29446394 | - | 5801 | 3660 | 143 | 5350 | 1735 | |
| ENST00000582970 | RNF213 | chr17 | 78302277 | ENST00000389048 | ALK | chr2 | 29446394 | - | 5801 | 3660 | 143 | 5350 | 1735 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP >74961_74961_1_RNF213-ALK_RNF213_chr17_78302277_ENST00000456466_ALK_chr2_29446394_ENST00000389048_length(amino acids)=1735AA_BP=1172 MECPSCQHVSKEETPKFCSQCGERLPPAAPIADSENNNSTMASASEGEMECGQELKEEGGPCLFPGSDSWQENPEEPCSKASWTVQESKK KKRKKKKKGNKSASSELASLPLSPASPCHLTLLSNPWPQDTALPHSQAQQSGPTGQPSQPPGTATTPLEGDGLSAPTEVGDSPLQAQALG EAGVATGSEAQSSPQFQDHTEGEDQDASIPSGGRGLSQEGTGPPTSAGEGHSRTEDAAQELLLPESKGGSSEPGTELQTTEQQAGASASM AVDAVAEPANAVKGAGKEMKEKTQRMKQPPATTPPFKTHCQEAETKTKDEMAAAEEKVGKNEQGEPEDLKKPEGKNRSAAAVKNEKEQKN QEADVQEVKASTLSPGGGVTVFFHAIISLHFPFNPDLHKVFIRGGEEFGESKWDSNICELHYTRDLGHDRVLVEGIVCISKKHLDKYIPY KYVIYNGESFEYEFIYKHQQKKGEYVNRCLFIKSSLLGSGDWHQYYDIVYMKPHGRLQKVMNHITDGPRKDLVKGKQIAAALMLDSTFSI LQTWDTINLNSFFTQFEQFCFVLQQPMIYEGQAQLWTDLQYREKEVKRYLWQHLKKHVVPLPDGKSTDFLPVDCPVRSKLKTGLIVLFVV EKIELLLEGSLDWLCHLLTSDASSPDEFHRDLSHILGIPQSWRLYLVNLCQRCMDTRTYTWLGALPVLHCCMELAPRHKDAWRQPEDTWA ALEGLSFSPFREQMLDTSSLLQFMREKQHLLSIDEPLFRSWFSLLPLSHLVMYMENFIEHLGRFPAHILDCLSGIYYRLPGLEQVLNTQD VQDVQNVQNILEMLLRLLDTYRDKIPEEALSPSYLTVCLKLHEAICSSTKLLKFYELPALSAEIVCRMIRLLSLVDSAGQRDETGNNSVQ TVFQGTLAATKRWLREVFTKNMLTSSGASFTYVKEIEVWRRLVEIQFPAEHGWKESLLGDMEWRLTKEEPLSQITAYCNSCWDTKGLEDS VAKTFEKCIIEAVSSACQSQTSILQGFSYSDLRKFGIVLSAVITKSWPRTADNFNDILKHLLTLADVKHVFRLCGTDEKILANVTEDAKR LIAVADSVLTKVVGDLLSGTILVGQLELIIKHKNQFLDIWQLREKSLSPQDEQCAVEEALDWRREELLLLKKEKRCVDSLLKMCGNVKHL IQVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPL QVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIAC GCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSL GYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRP KDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNP TYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEA -------------------------------------------------------------- >74961_74961_2_RNF213-ALK_RNF213_chr17_78302277_ENST00000508628_ALK_chr2_29446394_ENST00000389048_length(amino acids)=1784AA_BP=1221 MECPSCQHVSKEETPKFCSQCGERLPPAAPIADSENNNSTMASASEGEMECGQELKEEGGPCLFPGSDSWQENPEEPCSKASWTVQEGAT SEVLVDAAVDLISDEWEAANAIPSKRRKQDAAPLEAASVPSADCEQSKKKKRKKKKKGNKSASSELASLPLSPASPCHLTLLSNPWPQDT ALPHSQAQQSGPTGQPSQPPGTATTPLEGDGLSAPTEVGDSPLQAQALGEAGVATGSEAQSSPQFQDHTEGEDQDASIPSGGRGLSQEGT GPPTSAGEGHSRTEDAAQELLLPESKGGSSEPGTELQTTEQQAGASASMAVDAVAEPANAVKGAGKEMKEKTQRMKQPPATTPPFKTHCQ EAETKTKDEMAAAEEKVGKNEQGEPEDLKKPEGKNRSAAAVKNEKEQKNQEADVQEVKASTLSPGGGVTVFFHAIISLHFPFNPDLHKVF IRGGEEFGESKWDSNICELHYTRDLGHDRVLVEGIVCISKKHLDKYIPYKYVIYNGESFEYEFIYKHQQKKGEYVNRCLFIKSSLLGSGD WHQYYDIVYMKPHGRLQKVMNHITDGPRKDLVKGKQIAAALMLDSTFSILQTWDTINLNSFFTQFEQFCFVLQQPMIYEGQAQLWTDLQY REKEVKRYLWQHLKKHVVPLPDGKSTDFLPVDCPVRSKLKTGLIVLFVVEKIELLLEGSLDWLCHLLTSDASSPDEFHRDLSHILGIPQS WRLYLVNLCQRCMDTRTYTWLGALPVLHCCMELAPRHKDAWRQPEDTWAALEGLSFSPFREQMLDTSSLLQFMREKQHLLSIDEPLFRSW FSLLPLSHLVMYMENFIEHLGRFPAHILDCLSGIYYRLPGLEQVLNTQDVQDVQNVQNILEMLLRLLDTYRDKIPEEALSPSYLTVCLKL HEAICSSTKLLKFYELPALSAEIVCRMIRLLSLVDSAGQRDETGNNSVQTVFQGTLAATKRWLREVFTKNMLTSSGASFTYVKEIEVWRR LVEIQFPAEHGWKESLLGDMEWRLTKEEPLSQITAYCNSCWDTKGLEDSVAKTFEKCIIEAVSSACQSQTSILQGFSYSDLRKFGIVLSA VITKSWPRTADNFNDILKHLLTLADVKHVFRLCGTDEKILANVTEDAKRLIAVADSVLTKVVGDLLSGTILVGQLELIIKHKNQFLDIWQ LREKSLSPQDEQCAVEEALDWRREELLLLKKEKRCVDSLLKMCGNVKHLIQVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNY CFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVS LQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARD IYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCW QHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKP TAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVA -------------------------------------------------------------- >74961_74961_3_RNF213-ALK_RNF213_chr17_78302277_ENST00000582970_ALK_chr2_29446394_ENST00000389048_length(amino acids)=1735AA_BP=1172 MECPSCQHVSKEETPKFCSQCGERLPPAAPIADSENNNSTMASASEGEMECGQELKEEGGPCLFPGSDSWQENPEEPCSKASWTVQESKK KKRKKKKKGNKSASSELASLPLSPASPCHLTLLSNPWPQDTALPHSQAQQSGPTGQPSQPPGTATTPLEGDGLSAPTEVGDSPLQAQALG EAGVATGSEAQSSPQFQDHTEGEDQDASIPSGGRGLSQEGTGPPTSAGEGHSRTEDAAQELLLPESKGGSSEPGTELQTTEQQAGASASM AVDAVAEPANAVKGAGKEMKEKTQRMKQPPATTPPFKTHCQEAETKTKDEMAAAEEKVGKNEQGEPEDLKKPEGKNRSAAAVKNEKEQKN QEADVQEVKASTLSPGGGVTVFFHAIISLHFPFNPDLHKVFIRGGEEFGESKWDSNICELHYTRDLGHDRVLVEGIVCISKKHLDKYIPY KYVIYNGESFEYEFIYKHQQKKGEYVNRCLFIKSSLLGSGDWHQYYDIVYMKPHGRLQKVMNHITDGPRKDLVKGKQIAAALMLDSTFSI LQTWDTINLNSFFTQFEQFCFVLQQPMIYEGQAQLWTDLQYREKEVKRYLWQHLKKHVVPLPDGKSTDFLPVDCPVRSKLKTGLIVLFVV EKIELLLEGSLDWLCHLLTSDASSPDEFHRDLSHILGIPQSWRLYLVNLCQRCMDTRTYTWLGALPVLHCCMELAPRHKDAWRQPEDTWA ALEGLSFSPFREQMLDTSSLLQFMREKQHLLSIDEPLFRSWFSLLPLSHLVMYMENFIEHLGRFPAHILDCLSGIYYRLPGLEQVLNTQD VQDVQNVQNILEMLLRLLDTYRDKIPEEALSPSYLTVCLKLHEAICSSTKLLKFYELPALSAEIVCRMIRLLSLVDSAGQRDETGNNSVQ TVFQGTLAATKRWLREVFTKNMLTSSGASFTYVKEIEVWRRLVEIQFPAEHGWKESLLGDMEWRLTKEEPLSQITAYCNSCWDTKGLEDS VAKTFEKCIIEAVSSACQSQTSILQGFSYSDLRKFGIVLSAVITKSWPRTADNFNDILKHLLTLADVKHVFRLCGTDEKILANVTEDAKR LIAVADSVLTKVVGDLLSGTILVGQLELIIKHKNQFLDIWQLREKSLSPQDEQCAVEEALDWRREELLLLKKEKRCVDSLLKMCGNVKHL IQVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPL QVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIAC GCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSL GYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRP KDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNP TYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEA -------------------------------------------------------------- |
Top |
Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:/chr2:) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| RNF213 | ALK |
| FUNCTION: Atypical E3 ubiquitin ligase that can catalyze ubiquitination of both proteins and lipids, and which is involved in various processes, such as lipid metabolism, angiogenesis and cell-autonomous immunity (PubMed:21799892, PubMed:26126547, PubMed:26278786, PubMed:26766444, PubMed:30705059, PubMed:32139119, PubMed:34012115). Acts as a key immune sensor by catalyzing ubiquitination of the lipid A moiety of bacterial lipopolysaccharide (LPS) via its RZ-type zinc-finger: restricts the proliferation of cytosolic bacteria, such as Salmonella, by generating the bacterial ubiquitin coat through the ubiquitination of LPS (PubMed:34012115). Also acts indirectly by mediating the recruitment of the LUBAC complex, which conjugates linear polyubiquitin chains (PubMed:34012115). Ubiquitination of LPS triggers cell-autonomous immunity, such as antibacterial autophagy, leading to degradation of the microbial invader (PubMed:34012115). Involved in lipid metabolism by regulating fat storage and lipid droplet formation; act by inhibiting the lipolytic process (PubMed:30705059). Also regulates lipotoxicity by inhibiting desaturation of fatty acids (PubMed:30846318). Also acts as an E3 ubiquitin-protein ligase via its RING-type zinc finger: mediates 'Lys-63'-linked ubiquitination of target proteins (PubMed:32139119, PubMed:33842849). Involved in the non-canonical Wnt signaling pathway in vascular development: acts by mediating ubiquitination and degradation of FLNA and NFATC2 downstream of RSPO3, leading to inhibit the non-canonical Wnt signaling pathway and promoting vessel regression (PubMed:26766444). Also has ATPase activity; ATPase activity is required for ubiquitination of LPS (PubMed:34012115). {ECO:0000269|PubMed:21799892, ECO:0000269|PubMed:26126547, ECO:0000269|PubMed:26278786, ECO:0000269|PubMed:26766444, ECO:0000269|PubMed:30705059, ECO:0000269|PubMed:30846318, ECO:0000269|PubMed:32139119, ECO:0000269|PubMed:33842849, ECO:0000269|PubMed:34012115}. | FUNCTION: Catalyzes the methylation of 5-carboxymethyl uridine to 5-methylcarboxymethyl uridine at the wobble position of the anticodon loop in tRNA via its methyltransferase domain (PubMed:20123966, PubMed:20308323, PubMed:31079898). Catalyzes the last step in the formation of 5-methylcarboxymethyl uridine at the wobble position of the anticodon loop in target tRNA (PubMed:20123966, PubMed:20308323). Has a preference for tRNA(Arg) and tRNA(Glu), and does not bind tRNA(Lys)(PubMed:20308323). Binds tRNA and catalyzes the iron and alpha-ketoglutarate dependent hydroxylation of 5-methylcarboxymethyl uridine at the wobble position of the anticodon loop in tRNA via its dioxygenase domain, giving rise to 5-(S)-methoxycarbonylhydroxymethyluridine; has a preference for tRNA(Gly) (PubMed:21285950). Required for normal survival after DNA damage (PubMed:20308323). May inhibit apoptosis and promote cell survival and angiogenesis (PubMed:19293182). {ECO:0000269|PubMed:19293182, ECO:0000269|PubMed:20123966, ECO:0000269|PubMed:20308323, ECO:0000269|PubMed:21285950, ECO:0000269|PubMed:31079898}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - Not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Protein Structures |
| PDB and CIF files of the predicted fusion proteins * Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format. |
| Fusion protein PDB link (fusion AA seq ID in FusionPDB) | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | AA seq | Len(AA seq) |
| PDB file (1002) >>>1002.pdbFusion protein BP residue: 1172 CIF file (1002) >>>1002.cif | RNF213 | chr17 | 78302277 | ALK | chr2 | 29446394 | - | MECPSCQHVSKEETPKFCSQCGERLPPAAPIADSENNNSTMASASEGEME CGQELKEEGGPCLFPGSDSWQENPEEPCSKASWTVQESKKKKRKKKKKGN KSASSELASLPLSPASPCHLTLLSNPWPQDTALPHSQAQQSGPTGQPSQP PGTATTPLEGDGLSAPTEVGDSPLQAQALGEAGVATGSEAQSSPQFQDHT EGEDQDASIPSGGRGLSQEGTGPPTSAGEGHSRTEDAAQELLLPESKGGS SEPGTELQTTEQQAGASASMAVDAVAEPANAVKGAGKEMKEKTQRMKQPP ATTPPFKTHCQEAETKTKDEMAAAEEKVGKNEQGEPEDLKKPEGKNRSAA AVKNEKEQKNQEADVQEVKASTLSPGGGVTVFFHAIISLHFPFNPDLHKV FIRGGEEFGESKWDSNICELHYTRDLGHDRVLVEGIVCISKKHLDKYIPY KYVIYNGESFEYEFIYKHQQKKGEYVNRCLFIKSSLLGSGDWHQYYDIVY MKPHGRLQKVMNHITDGPRKDLVKGKQIAAALMLDSTFSILQTWDTINLN SFFTQFEQFCFVLQQPMIYEGQAQLWTDLQYREKEVKRYLWQHLKKHVVP LPDGKSTDFLPVDCPVRSKLKTGLIVLFVVEKIELLLEGSLDWLCHLLTS DASSPDEFHRDLSHILGIPQSWRLYLVNLCQRCMDTRTYTWLGALPVLHC CMELAPRHKDAWRQPEDTWAALEGLSFSPFREQMLDTSSLLQFMREKQHL LSIDEPLFRSWFSLLPLSHLVMYMENFIEHLGRFPAHILDCLSGIYYRLP GLEQVLNTQDVQDVQNVQNILEMLLRLLDTYRDKIPEEALSPSYLTVCLK LHEAICSSTKLLKFYELPALSAEIVCRMIRLLSLVDSAGQRDETGNNSVQ TVFQGTLAATKRWLREVFTKNMLTSSGASFTYVKEIEVWRRLVEIQFPAE HGWKESLLGDMEWRLTKEEPLSQITAYCNSCWDTKGLEDSVAKTFEKCII EAVSSACQSQTSILQGFSYSDLRKFGIVLSAVITKSWPRTADNFNDILKH LLTLADVKHVFRLCGTDEKILANVTEDAKRLIAVADSVLTKVVGDLLSGT ILVGQLELIIKHKNQFLDIWQLREKSLSPQDEQCAVEEALDWRREELLLL KKEKRCVDSLLKMCGNVKHLIQVYRRKHQELQAMQMELQSPEYKLSKLRT STIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQV SGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGV SLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIAC GCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRK GGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSN QEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEY CTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEE RSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNP PSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGL EGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYG | 1735 | |
| 3D view using mol* of 1002 (AA BP:1172) | ||||||||||
 | ||||||||||
| PDB file (1026) >>>1026.pdbFusion protein BP residue: 1221 CIF file (1026) >>>1026.cif | RNF213 | chr17 | 78302277 | ALK | chr2 | 29446394 | - | MECPSCQHVSKEETPKFCSQCGERLPPAAPIADSENNNSTMASASEGEME CGQELKEEGGPCLFPGSDSWQENPEEPCSKASWTVQEGATSEVLVDAAVD LISDEWEAANAIPSKRRKQDAAPLEAASVPSADCEQSKKKKRKKKKKGNK SASSELASLPLSPASPCHLTLLSNPWPQDTALPHSQAQQSGPTGQPSQPP GTATTPLEGDGLSAPTEVGDSPLQAQALGEAGVATGSEAQSSPQFQDHTE GEDQDASIPSGGRGLSQEGTGPPTSAGEGHSRTEDAAQELLLPESKGGSS EPGTELQTTEQQAGASASMAVDAVAEPANAVKGAGKEMKEKTQRMKQPPA TTPPFKTHCQEAETKTKDEMAAAEEKVGKNEQGEPEDLKKPEGKNRSAAA VKNEKEQKNQEADVQEVKASTLSPGGGVTVFFHAIISLHFPFNPDLHKVF IRGGEEFGESKWDSNICELHYTRDLGHDRVLVEGIVCISKKHLDKYIPYK YVIYNGESFEYEFIYKHQQKKGEYVNRCLFIKSSLLGSGDWHQYYDIVYM KPHGRLQKVMNHITDGPRKDLVKGKQIAAALMLDSTFSILQTWDTINLNS FFTQFEQFCFVLQQPMIYEGQAQLWTDLQYREKEVKRYLWQHLKKHVVPL PDGKSTDFLPVDCPVRSKLKTGLIVLFVVEKIELLLEGSLDWLCHLLTSD ASSPDEFHRDLSHILGIPQSWRLYLVNLCQRCMDTRTYTWLGALPVLHCC MELAPRHKDAWRQPEDTWAALEGLSFSPFREQMLDTSSLLQFMREKQHLL SIDEPLFRSWFSLLPLSHLVMYMENFIEHLGRFPAHILDCLSGIYYRLPG LEQVLNTQDVQDVQNVQNILEMLLRLLDTYRDKIPEEALSPSYLTVCLKL HEAICSSTKLLKFYELPALSAEIVCRMIRLLSLVDSAGQRDETGNNSVQT VFQGTLAATKRWLREVFTKNMLTSSGASFTYVKEIEVWRRLVEIQFPAEH GWKESLLGDMEWRLTKEEPLSQITAYCNSCWDTKGLEDSVAKTFEKCIIE AVSSACQSQTSILQGFSYSDLRKFGIVLSAVITKSWPRTADNFNDILKHL LTLADVKHVFRLCGTDEKILANVTEDAKRLIAVADSVLTKVVGDLLSGTI LVGQLELIIKHKNQFLDIWQLREKSLSPQDEQCAVEEALDWRREELLLLK KEKRCVDSLLKMCGNVKHLIQVYRRKHQELQAMQMELQSPEYKLSKLRTS TIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVS GMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVS LQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACG CQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKG GCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQ EVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYC TQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEER SPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPP SELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLE GSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGY | 1784 | |
| 3D view using mol* of 1026 (AA BP:1221) | ||||||||||
| ||||||||||
Top |
pLDDT score distribution |
| pLDDT score distribution of the predicted wild-type structures of two partner proteins from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
RNF213_pLDDT.png  |
ALK_pLDDT.png  |
| pLDDT score distribution of the predicted fusion protein structures from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
RNF213_ALK_1002_pLDDT.png (AA BP:1172) |
RNF213_ALK_1002_pLDDT_and_active_sites.png (AA BP:1172) |
RNF213_ALK_1002_violinplot.png (AA BP:1172) |
RNF213_ALK_1026_pLDDT.png (AA BP:1221) |
RNF213_ALK_1026_pLDDT_and_active_sites.png (AA BP:1221) |
RNF213_ALK_1026_violinplot.png (AA BP:1221) |
Top |
Ramachandran Plot of Fusion Protein Structure |
| Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this fusion protein peptide. |
| Fusion AA seq ID in FusionPDB and their Ramachandran plots |
| RNF213_ALK_1002.png |
 |
| RNF213_ALK_1026.png |
 |
Top |
Potential Active Site Information |
| The potential binding sites of these fusion proteins were identified using SiteMap, a module of the Schrodinger suite. |
| Fusion AA seq ID in FusionPDB | Site score | Size | D score | Volume | Exposure | Enclosure | Contact | Phobic | Philic | Balance | Don/Acc | Residues |
| 1002 | 1.049 | 317 | 1.047 | 858.529 | 0.449 | 0.771 | 1.031 | 0.749 | 1.09 | 0.687 | 0.615 | Chain A: 1235,1237,1238,1239,1240,1241,1242,1245,1 263,1265,1282,1286,1295,1311,1312,1313,1314,1315,1 317,1318,1320,1321,1324,1327,1362,1364,1368,1369,1 371,1384,1385,1386,1387,1388,1389,1390,1391,1405,1 406,1407,1408,1409,1410,1441,1442,1443,1449,1450,1 618,1620,1621,1622,1623,1625 |
| 1002 | 1.049 | 317 | 1.047 | 858.529 | 0.449 | 0.771 | 1.031 | 0.749 | 1.09 | 0.687 | 0.615 | Chain A: 1235,1237,1238,1239,1240,1241,1242,1245,1 263,1265,1282,1286,1295,1311,1312,1313,1314,1315,1 317,1318,1320,1321,1324,1327,1362,1364,1368,1369,1 371,1384,1385,1386,1387,1388,1389,1390,1391,1405,1 406,1407,1408,1409,1410,1441,1442,1443,1449,1450,1 618,1620,1621,1622,1623,1625 |
| 1026 | 1.042 | 134 | 1.11 | 545.37 | 0.693 | 0.661 | 0.782 | 0.678 | 0.695 | 0.977 | 0.837 | Chain A: 106,174,176,532,534,535,536,537,599,602,6 03,606,607,609,610,612,613,614,615,624,625,626,628 ,629,630,631,632,633,635,636,637,640,681,683,684,6 85,687,717,718,719 |
| 1026 | 1.042 | 134 | 1.11 | 545.37 | 0.693 | 0.661 | 0.782 | 0.678 | 0.695 | 0.977 | 0.837 | Chain A: 106,174,176,532,534,535,536,537,599,602,6 03,606,607,609,610,612,613,614,615,624,625,626,628 ,629,630,631,632,633,635,636,637,640,681,683,684,6 85,687,717,718,719 |
Top |
Potentially Interacting Small Molecules through Virtual Screening |
| The FDA-approved small molecule library molecules were subjected to virtual screening using the Glide. |
| Fusion AA seq ID in FusionPDB | ZINC ID | DrugBank ID | Drug name | Docking score | Glide gscore |
Top |
| Drug information from DrugBank of the top 20 interacting small molecules. |
| ZINC ID | DrugBank ID | Drug name | Drug type | SMILES | Drug group |
Top |
Biochemical Features of Small Molecules |
| ADME (Absorption, Distribution, Metabolism, and Excretion) of drugs using QikProp(v3.9) |
| ZINC ID | mol_MW | dipole | SASA | FOSA | FISA | PISA | WPSA | volume | donorHB | accptHB | IP | Human Oral Absorption | Percent Human Oral Absorption | Rule Of Five | Rule Of Three |
Top |
Drug Toxicity Information |
| Toxicity information of individual drugs using eToxPred |
| ZINC ID | Smile | Surface Accessibility | Toxicity |
Top |
Fusion Protein-Protein Interaction |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type from validated records (BIOGRID-3.4.160) |
| Gene | PPI interactors |
| RNF213 | tat, UBC, vpu, CBX2, CBX4, CBX6, EGFR, PLAC9, RNF213, TRIM23, GOLGA2, REL, TRIM27, TRIP6, UBXN11, KRT40, CD244, SCN2B, IFI16, PTPN1, MRPL50, RNASEH2B, Kif4, Ube2k, Rpl35, GAN, MCM2, ATOH1, DLK2, SIGLECL1, SDC2, LAMP3, CYLD, HNRNPL, UBE2M, USP15, LYAR, HNRNPK, ITPR3, UBE2L3, UBE2D2, ESR2, RNF123, KIAA1429, CTDP1, MTDH, CEBPD, UNC93B1, AHNAK2, COPE, CPNE8, GNB1, GTSE1, LMNA, NOLC1, PLOD2, RPS12, SCRIB, SMTN, SNRPD2, SRPR, TCEB2, TPM2, UACA, ORF7a, SH2D3C, HIST1H1A, nsp5, nsp2, nsp6, CIT, AURKB, CHMP4C, KIF14, TRIM66, FIS1, OCIAD1, SUMO2, BRD4, CUL4A, UBE2D3, BAG5, AR, ATG5, IGHM, SLC35G1, NPTN, OPALIN, EFNB1, GCGR, C19orf38, HCST, LOC388882, GPR17, C5AR1, UPK2, CD40, OSTM1, FPR1, TACSTD2, RELT, TMEM55B, VSIG4, HLA-B, TMEM9B, NPDC1, BSG, GPR45, FAM174A, STK16, GPR182, MFSD4, MGARP, CLEC4A, HS2ST1, FFAR1, SGCA, HLA-C, UBE2N, UBE2U, SLFN11, FBXW7, |
| Protein-protein interactors based on sequence similarity (STRING) |
| Gene | STRING network |
| RNF213 | |
| ALK |  |
| - Retained interactions in fusion protein (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost interactions due to fusion (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs to RNF213-ALK |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to RNF213-ALK |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| RNF213 | ALK | Lung Adenocarcinoma | MyCancerGenome | |
| RNF213 | ALK | Acute Myeloid Leukemia | MyCancerGenome | |
| RNF213 | ALK | Cancer Of Unknown Primary | MyCancerGenome | |
| RNF213 | ALK | Diffuse Large B-Cell Lymphoma | MyCancerGenome | |
| RNF213 | ALK | Not Otherwise Specified | MyCancerGenome | |
| RNF213 | ALK | Glioblastoma | MyCancerGenome |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | RNF213 | C1846689 | MOYAMOYA DISEASE 2 | 9 | CTD_human;UNIPROT |
| Hgene | RNF213 | C0026654 | Moyamoya Disease | 3 | ORPHANET |
| Hgene | RNF213 | C2931384 | Moyamoya disease 1 | 3 | ORPHANET |
| Tgene | ALK | C0007131 | Non-Small Cell Lung Carcinoma | 28 | CGI;CTD_human |
| Tgene | ALK | C0027819 | Neuroblastoma | 13 | CGI;CTD_human;ORPHANET |
| Tgene | ALK | C0152013 | Adenocarcinoma of lung (disorder) | 8 | CGI;CTD_human |
| Tgene | ALK | C2751681 | NEUROBLASTOMA, SUSCEPTIBILITY TO, 3 | 8 | CLINGEN;UNIPROT |
| Tgene | ALK | C0206180 | Ki-1+ Anaplastic Large Cell Lymphoma | 6 | CGI;CTD_human |
| Tgene | ALK | C0334121 | Inflammatory Myofibroblastic Tumor | 4 | CGI;CTD_human;ORPHANET |
| Tgene | ALK | C0018199 | Granuloma, Plasma Cell | 3 | CTD_human |
| Tgene | ALK | C0007621 | Neoplastic Cell Transformation | 2 | CTD_human |
| Tgene | ALK | C0027627 | Neoplasm Metastasis | 2 | CTD_human |
| Tgene | ALK | C0238463 | Papillary thyroid carcinoma | 2 | ORPHANET |
| Tgene | ALK | C0001973 | Alcoholic Intoxication, Chronic | 1 | PSYGENET |
| Tgene | ALK | C0006118 | Brain Neoplasms | 1 | CGI;CTD_human |
| Tgene | ALK | C0006142 | Malignant neoplasm of breast | 1 | CTD_human |
| Tgene | ALK | C0007134 | Renal Cell Carcinoma | 1 | CTD_human |
| Tgene | ALK | C0011570 | Mental Depression | 1 | PSYGENET |
| Tgene | ALK | C0011581 | Depressive disorder | 1 | PSYGENET |
| Tgene | ALK | C0027643 | Neoplasm Recurrence, Local | 1 | CTD_human |
| Tgene | ALK | C0036341 | Schizophrenia | 1 | PSYGENET |
| Tgene | ALK | C0079744 | Diffuse Large B-Cell Lymphoma | 1 | CTD_human |
| Tgene | ALK | C0085269 | Plasma Cell Granuloma, Pulmonary | 1 | CTD_human |
| Tgene | ALK | C0153633 | Malignant neoplasm of brain | 1 | CGI;CTD_human |
| Tgene | ALK | C0278601 | Inflammatory Breast Carcinoma | 1 | CTD_human |
| Tgene | ALK | C0279702 | Conventional (Clear Cell) Renal Cell Carcinoma | 1 | CTD_human |
| Tgene | ALK | C0496899 | Benign neoplasm of brain, unspecified | 1 | CTD_human |
| Tgene | ALK | C0678222 | Breast Carcinoma | 1 | CTD_human |
| Tgene | ALK | C0750974 | Brain Tumor, Primary | 1 | CTD_human |
| Tgene | ALK | C0750977 | Recurrent Brain Neoplasm | 1 | CTD_human |
| Tgene | ALK | C0750979 | Primary malignant neoplasm of brain | 1 | CTD_human |
| Tgene | ALK | C1257931 | Mammary Neoplasms, Human | 1 | CTD_human |
| Tgene | ALK | C1266042 | Chromophobe Renal Cell Carcinoma | 1 | CTD_human |
| Tgene | ALK | C1266043 | Sarcomatoid Renal Cell Carcinoma | 1 | CTD_human |
| Tgene | ALK | C1266044 | Collecting Duct Carcinoma of the Kidney | 1 | CTD_human |
| Tgene | ALK | C1306837 | Papillary Renal Cell Carcinoma | 1 | CTD_human |
| Tgene | ALK | C1332079 | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | ORPHANET |
| Tgene | ALK | C1458155 | Mammary Neoplasms | 1 | CTD_human |
| Tgene | ALK | C1527390 | Neoplasms, Intracranial | 1 | CTD_human |
| Tgene | ALK | C2931189 | Neural crest tumor | 1 | ORPHANET |
| Tgene | ALK | C3899155 | hereditary neuroblastoma | 1 | GENOMICS_ENGLAND |
| Tgene | ALK | C4704874 | Mammary Carcinoma, Human | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies